SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
___________________
Date of Report (Date of earliest event reported) November 19, 1998
BIOCONTROL TECHNOLOGY, INC.
(Exact name of registrant as specified in its charter)
Pennsylvania 0-10822 25-1229323
(State of other jurisdiction (Commission File Number) (IRS Employer
of incorporation) Identification No.)
300 Indian Springs Road, Indiana, Pennsylvania 15701
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (724) 349-1811
_________________________________________________________________
(Former name or former address,
if changes since last report.)
Item 1. Change in Control of Registrant.
Not applicable.
Item 2. Acquisition or Disposition of Assets.
Not applicable.
Item 3. Bankruptcy or Receivership.
Not applicable.
Item 4. Changes in Registrant's Certifying Accountant
Not applicable.
Item 5. Other Events.
Biocontrol Technology, Inc. announced today that the
company has received a $10 million equity line of credit
arranged by the New York City-based May Davis Group
investment banking firm. The Company expects to commence
utilizing this financing early in 1999 subject to an
affective registration statement.
Item 6. Resignation of Registrant's Directors.
Not applicable
Item 7. Financial Statement, Pro Forma Financial Information
and Exhibits.
(a) Financial Statements and Businesses Acquired
-Not Applicable.
(b) Pro Forma Financial Information - Not Applicable.
(c) Exhibits - Press Release.
SIGNATURES
Pursuant to the requirement of the Securities Exchange Act
of 1934, the Registrant has duly caused this Report to be signed
on its behalf by the undersigned hereunto duly authorized.
BIOCONTROL TECHNOLOGY, INC.
by /s/ Fred E. Cooper
Fred E. Cooper, CEO
DATED: November 19, 1998
Investors Media
Diane McQuaide Susan Taylor
1.412.429.0673 phone 1.412.429.0673 phone
1.412.279.9690 fax 1.412.279.5041 fax
BIOCONTROL RECEIVES $10 MILLION EQUITY LINE OF CREDIT
Pittsburgh, PA - November 19, 1998 - Biocontrol Technology, Inc.
(OTCBB:BICO) announced today that the company has received a $10 million
equity line of credit (LOC) arranged by the New York City-based May Davis
Group investment banking firm.
The Company expects to commence utilizing this financing early in
1999 subject to an effective registration statement.
Fred E. Cooper, Biocontrol chief executive officer, stated that
this line of credit demonstrates the strong financial support of the
company while efforts continue to arrange mergers, acquisitions, and
strategic alliances for the subsidiaries and licensing outside the US for
the Diasensor r 1000 noninvasive glucose sensor.
Biocontrol Technology, Inc. has its corporate offices in
Pittsburgh, PA and is involved in the development and manufacture of
biomedical devices and environmental products.
WEBSITE: www.bico.com
INVESTOR RELATIONS NEWSLINE NUMBER 1.800.357.6204
This press release contains forward looking statements and
shareholders and potential investors are cautioned that such
statements are predictions and actual events or results may vary
significantly.
